HIV Fat Redistribution and the Evaluation of Brown Fat

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

27 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-03-31

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The specific aims of this study are to determine whether HIV-infected patients with significant fat redistribution and ectopic fat accumulation have increased brown adipose tissue using 18F-FDG Positron Emission Tomography techniques.

Recent studies suggest down regulation of Dicer, a major component of miRNA has an important role in the differentiation and function of brown and white adipose tissue and may contribute to lipodystrophy. Therefore we will expand on recent research in this area by recruiting HIV-infected men with lipodystrophy. We will perform subcutaneous fat biopsies of the dorsocervical and abdominal fat in a subset of HIV-infected and non-HIV-infected men in order to explore further the question of down regulation of Dicer and its implication on metabolic abnormalities in this population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

NCT00119405

HIV Infections Lipodystrophy Metabolic Diseases +1 more

COMPLETED

Magnetic Resonance Imaging of the Face and Bones

NCT00001762

HIV Infection

COMPLETED

Adipose Tissue and Immune Activation in HIV

NCT04439448

Human Immunodeficiency Virus Obesity

COMPLETED

Metabolism and Body Shape of Healthy Children and Children With Chronic Infections

NCT00001142

HIV Infections Healthy Hyperlipidemia +1 more

COMPLETED

Mechanisms of Lipodystrophy in HIV-Infected Pateints

NCT00457665

HIV Infections

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Among individuals infected with HIV, highly active antiretroviral therapy has reduced the incidence of morbidity and mortality however, despite recent improvements in newer antiretrovirals patients continue to exhibit secondary effects related to body composition such as lipoatrophy of the periphery, increased adiposity of the trunk and lipomatosis, especially of the dorsocervical spine. Changes in body composition have been reported in 40-50% of HIV-infected patients. Several studies have shown that antiretroviral therapy contributes to changes in body composition and is coupled with increased dyslipidemia, insulin resistance and diabetes.

Accumulation of fat over the dorsocervical spine, or "buffalo" has been reported in 2% to 13% of HIV-infected patients. Enlargement of adipose tissue in the dorsocervical region involves subcutaneous fat and is therefore unique to fat accumulation of the abdominal area. Guallar et al. examined dorsocervical adipose tissue after surgical removal and found that adipose tissue in this area showed substantial levels of the marker gene of brown fat, uncoupling protein 1 (UCP-1) suggesting there may be brown adipose tissue (BAT) in HIV infected individuals with lipomatosis of the dorsocervical spine. Until recently, BAT was known to be present in rodents throughout their lifetime and was thought to be present in humans only during infancy and early childhood. However, recent studies using 18F-FDG PET-CT have confirmed the presence of BAT in adults. Brown adipose tissue is known to affect whole-body metabolism and may be related to insulin sensitivity as well as susceptibility to weight gain.

Using 18F-FDG PET techniques, our group has evaluated HIV-infected subjects with lipoatrophy and noted there was significantly increased glucose uptake into subcutaneous tissue which may suggest presence of BAT in HIV-infected patients. However our previous study did not specifically examine areas of BAT in the subjects. Therefore, using 18F-FDG PET-CT in addition to fat biopsies we propose to explore the presence of BAT in fat depots among HIV-infected patients with fat redistribution, focusing specifically in the cervical area.

Also, as recent studies suggest down regulation of Dicer, a major component of miRNA has an important role in the differentiation and function of brown and white adipose tissue and may contribute to lipodystrophy. We will perform subcutaneous fat biopsies of the dorsocervical and abdominal fat in a subset of HIV-infected and non-HIV-infected men in order to explore further the question of down regulation of Dicer and its implication on metabolic abnormalities in this population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV-infection with fat redistribution (lipoatrophy)

1. Evidence of HIV infection
2. Age ≥ 20 and ≤ 60 years of age
3. BMI measurement between 18-24 kg/m2
4. HIV positive, on a stable HAART treatment regimen (including an NRTI) for \> 12 months
5. No evidence of fat redistribution rated by the investigator.

No interventions assigned to this group

Healthy controls

1. No history of HIV infection
2. Age ≥ 20 and ≤ 60 years of age
3. BMI measurement between 18-29.9 kg/m2

No interventions assigned to this group

HIV-infected with fat redistribution (lipohypertrophy)

1. Evidence of HIV infection
2. Age ≥ 20 and ≤ 60 years of age
3. BMI measurement between 25-29.9 kg/m2
4. HIV positive, on a stable HAART treatment regimen (including an NRTI) for \> 12 months
5. Evidence of significant fat redistribution rated by the investigator, including 1) significant fat atrophy of the face, arms or legs, and 2) significant increase in fat accumulation of the neck.

No interventions assigned to this group

Dicer Cohort

30 men \[HV-infected with fat redistribution (n = 10), HIV-infected without fat redistribution (n=10), and healthy controls (n= 10)\] will be recruited for this group.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Evidence of HIV infection
2. Age ≥ 20 and ≤ 60 years of age
3. BMI measurement between 25-29.9 kg/m2
4. HIV positive, on a stable HAART treatment regimen (including an NRTI) for \> 12 months
5. Evidence of significant fat redistribution rated by the investigator, including 1) significant fat atrophy of the face, arms or legs, and 2) significant increase in fat accumulation of the neck.

1. Evidence of HIV infection
2. Age ≥ 20 and ≤ 60 years of age
3. BMI measurement between 18-24 kg/m2
4. HIV positive, on a stable HAART treatment regimen (including an NRTI) for \> 12 months
5. No evidence of fat redistribution rated by the investigator.

1. No history of HIV infection
2. Age ≥ 20 and ≤ 60 years of age
3. BMI measurement between 18-29.9 kg/m2

Exclusion Criteria

1. Hemoglobin \< 10.0 g/dL
2. Diabetes or on medications for diabetes
3. Abnormal thyroid function
4. Therapy with medications such as beta blockers, alpha-blockers, sympatholytic drugs
5. Chronic adrenergic drug use (\>3 months) and benzodiazepine use.
6. Therapy with glucocorticoids (oral and inhaled), growth hormone or other anabolic agents currently or within the past 3 months
7. Current substance abuse, including alcohol, cocaine and/or heroin
8. Other serious or chronic diseases
9. New antiretroviral regimen in the past 12 months
10. Any new serious opportunistic infection within the past 6 weeks

1. Hemoglobin \< 10.0 g/dL
2. Diabetes or on medications for diabetes
3. Abnormal thyroid function
4. Therapy with medications such as beta blockers, alpha-blockers, sympatholytic drugs
5. Chronic adrenergic drug use (\>3 months) and benzodiazepine use.
6. Therapy with glucocorticoids (oral and inhaled), growth hormone or other anabolic agents currently or within the past 3 months
7. Current substance abuse, including alcohol, cocaine and/or heroin
8. Other serious or chronic diseases
9. New antiretroviral regimen in the past 12 months
10. Any new serious opportunistic infection within the past 6 weeks

1. Hemoglobin \<10.0 g/dL.
2. Diabetes or on medications for diabetes
3. Abnormal thyroid function.
4. Therapy with medications such as beta blockers, alpha-blockers, sympatholytic drugs
5. Chronic adrenergic drug use (\>3 months) and benzodiazepine use.
6. Therapy with glucocorticoid (oral and inhaled), growth hormone or other anabolic agents currently or within the past 3 months
7. Current substance abuse, including alcohol, cocaine and/or heroin
8. Any history of serious or chronic diseases -

Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes